Pharmacological Treatments in Heart Failure With Mildly Reduced and Preserved Ejection Fraction
JACC: Heart Failure · 2024
DOI: 10.1016/j.jchf.2023.07.014 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift JACC: Heart Failure, 2024. Verfasst von Stefanos Zafeiropoulos und 11 weiteren Autor:innen. Beteiligte Einrichtung: Elmezzi Graduate School of Molecular Medicine, Northwell Health, Manhasset, New York, USA; Feinstein Institutes for Medical Research at Northwell Hea…. Hauptthemen laut MEDLINE: Heart Failure. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
BACKGROUND: Medical treatment for heart failure with preserved ejection (HFpEF) and heart failure with mildly reduced ejection fraction (HFmrEF) has weaker evidence compared with reduced ejection fraction, despite recent trials with an angiotensin receptor neprilysin inhibitor (ARNI) and sodium glucose co-transporter 2 inhibitors (SGLT2is). OBJECTIVES: The authors aimed to estimate the aggregate therapeutic benefit of drugs for HFmrEF and HFpEF. METHODS: The authors performed a systematic review of MEDLINE, CENTRAL, and Web of Science for randomized trials including patients with heart failure (HF) and left ventricular ejection fraction (LVEF) >40%, treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (analyzed together as renin-angiotensin system inhibitors [RASi]), beta-blockers (BBs), mineralocorticoid receptor antagonists (MRAs), digoxin, ARNI, and SGLT2i. An additive component network meta-analysis was performed. The primary outcome was a composite of cardiovascular (CV) death and first hospitalization for heart failure (HHF); secondary outcomes were CV death, total HHF, and all-cause mortality. RESULTS: The authors identified 13 studies with a total of 29,875 patients and a mean LVEF of 56.3% ± 8.7%. ARNI, MRA, and SGLT2i separately, but not RASi, BB, or digoxin, reduced the primary composite outcome compared with placebo. The combination of ARNI, BB, MRA, and SGLT2i was the most effective (HR: 0.47 [95% CI: 0.31-0.70]); this was largely explained by the triple combination of ARNI, MRA, and SGLT2i (HR: 0.56 [95% CI 0.43-0.71]). Results were similar for CV death (HR: 0.63 [95% CI 0.43-0.91] for ARNI, MRA, and SGLT2i) or total HHF (HR: 0.49 [95% CI 0.33-0.71] for ARNI, MRA, and SGLT2i) alone. In a subgroup analysis, only SGLT2i had a consistent benefit among all LVEF subgroups, whereas the triple combination had the greatest benefit in HFmrEF, robust benefit in patients with LVEF 50% to 59%, and a statistically marginal benefit in patients with LVEF ≥60%. CONCLUSIONS: In patients with HF and LVEF>40%, the quadruple combination of ARNI, BB, MRA, and SGLT2i provides the largest reduction in the risk of CV death and HHF; driven by the robust effect of the triple combination of ARNI, MRA, and SGLT2i. The benefit was more pronounced in HFmrEF patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Elmezzi Graduate School of Molecular Medicine, Northwell Health, Manhasset, New York, USA; Feinstein Institutes for Medical Research at Northwell Health, Manhasset, New York, USA.
- Center for Thrombosis and Hemostasis, University Medical Center Mainz, Germany; Department of Cardiology, AHEPA University Hospital, Thessaloniki, Greece.
- Harrington Heart and Vascular Institute, University Hospitals, Cleveland, Ohio, USA.
- Athens Heart Center, Athens Medical Center, Athens, Greece; First Department of Cardiology, National and Kapodistrian University, "Hippokration" Hospital, Athens, Greece.
- Center for Thrombosis and Hemostasis, University Medical Center Mainz, Germany; Department of Cardiology, Democritus University of Thrace, Alexandroupoli, Greece.
- Feinstein Institutes for Medical Research at Northwell Health, Manhasset, New York, USA; Department of Cardiology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, North Shore University Hospital, Manh…
Zitieren
APA
Zafeiropoulos, S., Farmakis, I. T., Milioglou, I., Doundoulakis, I., Gorodeski, E. Z., Konstantinides, S. V., Cooper, L., Zanos, S., Stavrakis, S., Giamouzis, G., Butler, J., & Giannakoulas, G. (2024). Pharmacological Treatments in Heart Failure With Mildly Reduced and Preserved Ejection Fraction. JACC: Heart Failure. https://doi.org/10.1016/j.jchf.2023.07.014
Vancouver
Zafeiropoulos S, Farmakis IT, Milioglou I, Doundoulakis I, Gorodeski EZ, Konstantinides SV, et al. Pharmacological Treatments in Heart Failure With Mildly Reduced and Preserved Ejection Fraction. JACC: Heart Failure. 2024. doi:10.1016/j.jchf.2023.07.014
BibTeX
@article{Zafeiropoulos2024,
author = {Zafeiropoulos, Stefanos and Farmakis, Ioannis T and Milioglou, Ioannis and Doundoulakis, Ioannis and Gorodeski, Eiran Z and Konstantinides, Stavros V and Cooper, Lauren and Zanos, Stavros and Stavrakis, Stavros and Giamouzis, Grigorios and Butler, Javed and Giannakoulas, George},
title = {Pharmacological Treatments in Heart Failure With Mildly Reduced and Preserved Ejection Fraction},
journal = {JACC: Heart Failure},
year = {2024},
doi = {10.1016/j.jchf.2023.07.014}
}
EUVIMED